Loading BMY detail
Loading ticker data...
Loading BMY detail
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide.
It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Chart data unavailable
BMY stock jumps 10% in a month as growth drugs power revenues, but generic erosion and 2026 sales outlook keep investors cautious.
CVS Health and Bristol Myers Squibb are built to handle the toughest recessions. Both companies have maintained or increased their dividends through downturns over the past two decades.
BMY's Cobenfy gains traction with $155M in 2025 sales, outpacing peers and showing strong uptake as Bristol Myers eyes new indications and growth.
Oxford, UK and San Jose, California , 9 April 2026 – Oxford BioTherapeutics (“OBT”), is a clinical stage oncology company focused on the discovery and development of immuno-oncology (IO) and Antibody Drug Conjugate (ADC)-based therapies enabled by its OGAP®-Verify platform today announced a multi-year, selective target collaboration with Bristol Myers Squibb (NYSE: BMY, “BMS”) focussed on the discovery and development of novel T-cell engager therapies for solid tumours.
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $59.2, indicating a +2.65% shift from the previous trading day.
Leo Wealth LLC increased its stake in Bristol Myers Squibb Company (NYSE: BMY) by 36.8% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,134 shares of the biopharmaceutical company's stock after acquiring an additional 14,033 shares
Savvy Advisors Inc. raised its holdings in shares of Bristol Myers Squibb Company (NYSE: BMY) by 20.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 57,170 shares of the biopharmaceutical company's stock after purchasing an additional 9,893 shares during the period. Savvy Advisors Inc.'s holdings
Perpetual Ltd raised its position in shares of Bristol Myers Squibb Company (NYSE: BMY) by 121.2% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,741 shares of the biopharmaceutical company's stock after buying an additional 36,562 shares during the
Element Squared LLC bought a new position in Bristol Myers Squibb Company (NYSE: BMY) in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 48,420 shares of the biopharmaceutical company's stock, valued at approximately $2,612,000. Bristol Myers Squibb makes up approximately
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bristol Myers Squibb Company (NYSE: BMY - Get Free Report) EVP David Elkins sold 30,000 shares of the firm's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248
BridgePort Financial Solutions LLC grew its stake in Bristol Myers Squibb Company (NYSE: BMY) by 228.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,021 shares of the biopharmaceutical company's stock after buying an additional 11,143 shares during the period. BridgePort
Compagnie Lombard Odier SCmA reduced its position in shares of Bristol Myers Squibb Company (NYSE: BMY) by 99.2% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,000 shares of the biopharmaceutical company's stock after selling 238,000 shares
JANX earns $35M milestone payment from Bristol Myers as TRACTr-based cancer candidate advances, signaling progress in its tumor-activated therapy platform.
U.S. President Donald Trump secured agreements with 16 major pharmaceutical companies to bring U.S. prescription drug prices in line with those paid in other developed nations in exchange for three-year exemptions from tariffs on drug imports.
